)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Valeo Pharma
Valeo Pharma (VPH) investor relations material
Valeo Pharma has been otc
Valeo Pharma Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary13 Sep, 2024
Executive summary
Q3 2024 revenues were CAD 12.6 million, down 11% year-over-year, mainly due to the loss or termination of Xiidra commercialization, but core business/brands grew 9% year-over-year.
Adjusted EBITDA loss improved to CAD 1.5 million in Q3 2024 from CAD 2.5 million in Q3 2023, a 40% reduction.
Net loss for Q3 2024 was CAD 8.2 million, a 40% increase from Q3 2023, impacted by Xiidra loss and restructuring costs.
Cost-saving initiatives and restructuring have been implemented, with further OpEx reductions expected.
Enerzair and Atectura prescriptions rose 74% year-over-year, with prescribing physicians up 71%.
Financial highlights
Q3 2024 adjusted gross profit was CAD 3.9 million, down 12% year-over-year, mainly due to Xiidra transfer.
Year-to-date revenues were CAD 40.3 million, nearly flat compared to the prior year.
Year-to-date adjusted EBITDA loss improved 5% to CAD 6.1 million.
Year-to-date net loss was CAD 22.9 million, up from CAD 18.6 million the prior year.
Year-to-date adjusted gross profit was CAD 11.2 million, down 14% year-over-year.
Outlook and guidance
Continued revenue growth expected from core therapeutic assets and further OpEx reductions.
Targeting EBITDA positive in Q1 2025.
Cost reduction measures from respiratory business restructuring expected to decrease annual operating expenses by over CAD 5 million.
Anticipates explosive growth for REDESCA as Ontario market impact materializes in coming quarters.
Ongoing business development to expand the ophthalmology portfolio.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Valeo Pharma
Valeo Pharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Valeo Pharma Inc. is a specialty pharmaceutical company engaged in the acquisition, in-licensing brands and sale of pharmaceutical products with primary focus on respiratory, speciality and hospital generic products in Canada. The Company's core competencies include clinical research, regulatory affairs and drug safety. The Company focuses on marketing approved products through its prescription division as well as niche markets such as respiratory through specialty divisions.